3 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $35M | -$11M | 59.3% | -16.2% | -$10M | — | $23M |
| 2024 | $25M | -$13M | 55.4% | -27.7% | -$10M | — | $2M |
| 2023 | $13M | -$13M | 44.5% | -78.6% | -$10M | — | $5M |
Over the past 2 years, BIOHARVEST SCIENCES INC.'s revenue has grown 65.0% per year. These are computed facts, not advice.
As of FY2025, BIOHARVEST SCIENCES INC. reported — of total debt against $23M of cash.
In FY2025, gross margin was 59.3%, operating margin -16.2%, and net margin -32.3%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.